Search for information about a product,
therapeutic area or event

Media, investors, advocacy organizations and others, please contact us here.

PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 Months vs >12 Months From Kidney Biopsy

Page 1 / 1 100%
Loading...